We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quality of Life in Younger Leukemia and Lymphoma Survivors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00956475
First Posted: August 11, 2009
Last Update Posted: August 24, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
  Purpose

RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment.

PURPOSE: This phase I trial is studying quality of life in younger leukemia and lymphoma survivors.


Condition Intervention Phase
Anxiety Disorder Cancer Survivor Fatigue Leukemia Long-term Effects Secondary to Cancer Therapy in Adults Lymphoma Lymphoproliferative Disorder Pain Psychosocial Effects of Cancer and Its Treatment Small Intestine Cancer Behavioral: telephone-based intervention Other: questionnaire administration Procedure: assessment of therapy complications Procedure: fatigue assessment and management Procedure: psychosocial assessment and care Procedure: quality-of-life assessment Phase 1

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Quality of Life in Young Adult Survivors of Hematologic Malignancies

Resource links provided by NLM:


Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:
  • Quality of life [ Time Frame: 1-10 years after treatment ]
  • Most common areas of concern [ Time Frame: 1-10 years after treatment ]

Enrollment: 48
Study Start Date: October 2008
Study Completion Date: August 2011
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: telephone-based intervention
    Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
    Other: questionnaire administration
    Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
    Procedure: assessment of therapy complications
    questionnaire via telephone
    Procedure: fatigue assessment and management
    questionnaire via telephone
    Procedure: psychosocial assessment and care
    questionnaire via telephone
    Procedure: quality-of-life assessment
    questionnaire via telephone
Detailed Description:

OBJECTIVES:

  • To collect preliminary data to determine the extent to which there is impairment in quality of life of young adult survivors of hematologic malignancies.
  • To identify the most common areas of concern in these survivors.
  • To explore patterns of quality-of-life impairment associated with age, gender, and type of treatment (transplant vs non-transplant) in these survivors.

OUTLINE: Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Records from the practice of the study investigators will be reviewed to identify patients.
Criteria

DISEASE CHARACTERISTICS:

  • Survivors of leukemia (i.e., acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or chronic lymphocytic leukemia) or lymphoma (i.e., non-Hodgkin lymphoma or Hodgkin lymphoma) who have received any cytotoxic or radiation therapy
  • Received treatment for leukemia or lymphoma 1-10 years ago

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00956475


Locations
United States, Ohio
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Regan Demshar, RN Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
  More Information

Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00956475     History of Changes
Other Study ID Numbers: CASE11Z08
P30CA043703 ( U.S. NIH Grant/Contract )
CASE11Z08 ( Other Identifier: Case Comprehensive Cancer Center )
CASE 11Z08-CC607 ( Other Identifier: Cancer Center IRB )
First Submitted: August 8, 2009
First Posted: August 11, 2009
Last Update Posted: August 24, 2011
Last Verified: August 2011

Keywords provided by Case Comprehensive Cancer Center:
anxiety disorder
long-term effects secondary to cancer therapy in adults
fatigue
pain
psychosocial effects of cancer and its treatment
cancer survivor
accelerated phase chronic myelogenous leukemia
acute undifferentiated leukemia
adult acute lymphoblastic leukemia in remission
adult acute myeloid leukemia in remission
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
atypical chronic myeloid leukemia
blastic phase chronic myelogenous leukemia
chronic myelomonocytic leukemia
chronic phase chronic myelogenous leukemia
mast cell leukemia
meningeal chronic myelogenous leukemia
progressive hairy cell leukemia, initial treatment
prolymphocytic leukemia
recurrent adult acute lymphoblastic leukemia
recurrent adult acute myeloid leukemia
refractory chronic lymphocytic leukemia
refractory hairy cell leukemia
relapsing chronic myelogenous leukemia
secondary acute myeloid leukemia
stage I chronic lymphocytic leukemia

Additional relevant MeSH terms:
Lymphoma
Disease
Leukemia
Neoplasm Metastasis
Fatigue
Anxiety Disorders
Lymphoproliferative Disorders
Intestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pathologic Processes
Neoplastic Processes
Signs and Symptoms
Mental Disorders
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases